TAXUS Clinical Program

A Success Story Continues with TAXUS IV
In September of 2003, we learned that our pivotal U.S. clinical trial, TAXUS IV, had delivered just what we had hoped for: large-scale confirmation of the safety and efficacy of our paclitaxel-eluting coronary stent system in reducing restenosis.

The TAXUS IV results were groundbreaking. The data for target lesion revascularization (TLR), target vessel revascularization (TVR), and major adverse cardiac events (MACE) proved to be the lowest ever reported in a pivotal U.S. drug-eluting stent trial. The benefits reported at nine months were also maintained at twelve months, further reinforcing the power of the data and the TAXUS system. In challenging cases such as diabetics, small vessels and long lesions, the benefits were also maintained.